key: cord-0773905-5vxmvqoa
authors: Brunnhoelzl, Daniel; Hanania, Alexander N.; Echeverria, Alfredo; Sunde, Jan; Tran, Connie; Ludwig, Michelle
title: Paracervical Blocks Facilitate Timely Brachytherapy Amidst COVID-19
date: 2020-08-07
journal: Brachytherapy
DOI: 10.1016/j.brachy.2020.08.002
sha: 3a057221f70a05c3afc3372cf7e60cac1af6cdc7
doc_id: 773905
cord_uid: 5vxmvqoa

Structured Abstract Purpose The COVID-19 pandemic presents serious challenges for brachytherapists, and in the time-sensitive case of locally advanced cervical cancer (LACC), the need for curative brachytherapy (BT) is critical for survival. Given the high-volume of LACC in our safety-net hospital, we developed a strategy in close collaboration with our gynecology oncology and anesthesia colleagues to allow for completely clinic-based ICBT. Methods This technical report will highlight our experience with the use of paracervical blocks (PCB) and oral multimodal analgesia (MMA) for appropriately selected cervical ICBT cases, allowing for completely clinic-based treatment. Results 18 of 19 (95%) screened patients were eligible for in-clinic ICBT. The excluded patient had significant vaginal fibrosis. 38 of 39 intracavitary implants were successfully transitioned for entirely in-clinic treatment utilizing PCB and oral MMA (97% success rate). One case was aborted due to inadequate analgesia secondary to a significantly delayed case start time (PO medication effect diminished). 95% of patients reported no pain at the conclusion of the procedure. The median (IQR) D2cc for rectum and bladder were 64.8 (58.6-70.2) Gy and 84.1 (70.9-89.4) Gy, respectively. Median (IQR) CTV High Risk D90 was 88.0 (85.6-89.8) Gy. Conclusions In a multi-disciplinary effort, we have successfully transitioned many ICBT cases to the clinic with the use of PCB local anesthesia and oral multimodality therapy in direct response to the current pandemic, thereby mitigating exposure risk to patients and staff as well as reducing overall health care burden.

For cervical gynecological malignancies, overall treatment time ≤7 weeks (including brachytherapy boost) is necessary for optimal local control [1] . During COVID-19, many procedures are being postponed. Substitution of brachytherapy (BT) in cervical cancer is associated with a worse overall survival [2] . Further, the American Brachytherapy Society (ABS) have issued guidance that brachytherapy boost for cervical cancer should not be delayed under any circumstance for a patient not displaying COVID-19 symptoms [3] . Each operative encounter puts our immunocompromised patients at nosocomial risk, especially if general anesthesia is required wherein the generation of aerosols during intubation increases risk to staff and physicians [4] . Given that hospital resources, operative time slots, anesthesia, nursing personnel, and personal protective equipment (PPE) may be limited, a physician must employ judicious use of these precious resources. Therefore, we must balance timely brachytherapy with reducing high-risk events. This technical report will highlight a strategy developed in close collaboration with our gynecology and anesthesia colleagues in order to utilize paracervical blocks (PCBs) with multimodal oral analgesia for appropriately selected BT cases, thus allowing for treatment to be completely ambulatory.

Prior to COVID-19 pandemic, the workflow for ICBT insertions within our system was as follows: patient check-in at hospital around 6 am; patient goes to pre-operative area, consent check, anesthesia evaluation, and brachytherapists greet patient confirming procedure and site. Patient then brought to OR around 7:30 am, and a typical case will conclude around 9:30 am. Patient then brought to PACU where they await clearance for transport by anesthesia. Once cleared, the patient is transported to our clinic usually by 11 am. They have CT simulation; contouring of targets and OAR, and then 3D planning utilizing Eclipse with MRI fusions is completed. The prescription and fractionation is ~24 Gy in 3 fractions (per Rao et al) [5] with CT-based planning using parameters from EMBRACE II protocol. Treatment is then J o u r n a l P r e -p r o o f insertion include a good physical examination, and the ability to dilate the cervix and place a smit sleeve to make future tandem insertions swift and tolerable. While one way to decrease this risk is spinal anesthesia, as was mentioned in a recent article [6] discussing proposed changes in the COVID-19 era, an anesthesiologist or CNA is still required, which may be a difficult and limited request in the setting of pandemic or in a clinic not associated with a hospital. Additionally, results from Lim et al revealed that general anesthesia causes more complications than local or topical anesthesia [7] . At our institution, an attractive alternative was proposed for PO multimodal analgesia with PCB. Multimodal analgesia utilizes a combination of analgesics acting on different targets of the pain pathway (i.e. NSAIDs, acetaminophen, gabapentinoids, NMDA receptor antagonists, etc) in order to create synergistic analgesia [8] . This technique reduces opioid requirements and their side effects [9] . Multimodal anesthesia is accomplished using two or more drugs of different classes, followed by neuraxial analgesia, regional block, or local infiltration [10] . With the help of our anesthesia faculty, we therefore developed a PO regimen suitable for clinic use [ Table 1 ].

The method presented here allows the patient to arrive at our clinic around 7 am. They are then brought back to brachytherapy suite by nursing staff who also confirm that the patient has taken PO medications (and we encourage patients to bring medications with them so there is certainty). Patient is placed in stirrups and generally case begins around 7:30 am with examination, PCB, and then device insertion and packing. Patient is then taken to CT sim around 8:15 am. Contouring and treatment planning then occurs (3D planning as before) between 8:30-9:30 am. The treatment fraction is administered, device pulled, and patient discharged with a responsible adult as early as 10 am. Therefore, inclinic insertion with PCB takes 3 hours for a typical procedure, whereas operating room-based technique care delivery requires approximately 6 hours for most cases [Fig 1] .

The literature demonstrating benefit of PCB for pain reduction during cervical dilation is consistent. Subjectively, women reported pain of 1.5/10 with PCB versus 6.5/10 with saline during hysteroscopy and endometrial biopsy in one randomized trial [11] . Another randomized trial of PCB evaluating 120 patients found that pain during cervical dilation decreased from 80 to 40 of 100 mm measured using a Visual Analog Scale (VAS) [12] . A Cochrane review in 2013 of PCB J o u r n a l P r e -p r o o f found a significant reduction of pain with cervical dilation, with a lesser effect on uterine manipulation [13] . A randomized trial applicable to brachytherapy found a significant pain reduction (13 mm vs 54 mm on pain VAS) in patients undergoing laminaria placement, a procedure similar to dilation for brachytherapy, in which only mild uterine manipulation is anticipated [14] . Despite the successful implementation of PCBs in several brachytherapy clinics internationally, adoption of brachytherapist-directed local anesthesia in the US has been limited [15] [16] [17] .

Initially, we invited gynecologic oncology faculty to host a departmental in-service discussing the evidence for and technical aspects of performing PCB. Our faculty, residents, nurses, and other members of clinic leadership were in attendance. For the first case, we began with a patient also undergoing general anesthesia and were fortunate to be accompanied by our gynecologic oncologist to the operating room, who provided expert instruction and supervision. In order to allow for increased comfort with technique, our brachytherapists performed several cases in the operating room using PCB with PO multimodal analgesia and anesthesia on standby as monitored anesthesia care (MAC). For these cases we attempted to mimic in-clinic conditions, therefore no smit sleeve was placed; this has the added benefit of preventing uterine dilation and the associated discomfort. Initially, faculty performed the PCB with residents present to observe and then proceed with device insertion under supervision, as per standard practices of our residency program.

Once faculty were comfortable with the PCB, and residents had observed at least one case, the PCB was then performed by the resident with radiation oncology faculty oversight. Approximately 3 weeks passed between the first insertion in the OR with gynecologic oncologist instruction and the first procedure performed independently in-clinic with clinic leadership and other brachytherapy attendings in attendance as a proof of concept. These procedures were welltolerated, and at this time was able to be completed by a resident with direct attending supervision throughout. The general sentiment among faculty and residents was that the technique was quite simple and similar to the placement of a shallow fiducial marker with an interstitial needle.

Candidates for PO multimodal anesthesia with PCB undergo a BT planning MRI to assess response to external beam and ensure normal uterine geometry (i.e. no significant retroversion). Radiologic evidence of a patent cervical os, J o u r n a l P r e -p r o o f and the ability to directly visualize the cervix (which we assessed during a patient's final weekly encounter) are both reassuring. Whereas, patients with significant fibrosis of the vaginal canal, or who poorly tolerate pelvic exam may not be good candidates. The uterine angle and length are measured on the MRI to avoid use of the uterine sound. Shared decision-making is initiated with the patient at the time of BT planning to evaluate the patient's goals and willingness to proceed with the procedure in the clinic setting. In general, we have found that multiparous individuals with a history of vaginal delivery often tolerate the procedure well. Patients with severe psychiatric comorbidities, history of PTSD, or sexual trauma survivors might not be ideal candidates for an in-clinic procedure. Finally, American Society of Anesthesiologists (ASA) physical status classification should be II or less (mild diseases only without substantive functional limitations). Examples include (but not limited to): current smoker, social alcohol drinker, obesity, wellcontrolled DM/HTN, mild lung disease) [18] .

The patient is instructed to take 800 mg ibuprofen, 4 mg hydromorphone, 2 mg lorazepam, 25 mg promethazine, and 300 mg gabapentin orally, 60 minutes prior to the procedure. Of note, these doses are approximate and may be tailored to a patient's weight and history of narcotic use, allergies, anxiety level, and symptoms during their external beam course. Ensure the patient has 1:1 nursing coverage throughout the procedure for conversational support. Vital monitoring, including heart rate, blood pressure, respiratory rate and pulse oximetry should be checked every fifteen minutes during the procedure. Our clinic uses 10 mL of 1% lidocaine without epinephrine (although some protocols use up to 20 mL) [12] injected in equal amounts (5 mL) at 4 and 8 o'clock at the cervical-vaginal junction (fornix) at about 2 cm depth [Fig 2] . A critical step is to gently aspirate prior to injection to ensure the needle has not pierced a vessel. If the patient reacts readily to the insertion of the needle, attempt to inject slightly posteriorly to avoid direct contact on the utero-sacral ligament. Care should always be taken to avoid the 3 and 9 o'clock locations to avoid injury to the uterine artery. Inject slowly over a 30 second period (take more time if larger volume of lidocaine is used) while gently withdrawing using a 20-or 22-gauge spinal needle of 3.5-5 cm length. A spinal needle is preferable for this procedure due to the lower piercing effect of the pencil point tip compared to standard needles. Allow at least 3 minutes for the lidocaine to provide full anesthetic effect [12, 19] . In some cases, we applied up to 10 mL of 2% lidocaine J o u r n a l P r e -p r o o f gel to the vaginal canal prior to PCB. This diminished the discomfort of administering the PCB, and theoretically helps with discomfort during packing. In the case of minor bleeding from the injection site, apply gentle pressure with gauze attached to end of ring forceps to achieve hemostasis.

PCB is a low risk procedure and the dose of lidocaine is well below the lethal dose (4.5 mg/kg without epinephrine). Important considerations in the choice between lidocaine and bupivacaine are onset and duration of action. Lidocaine has an onset of about 2-3 minutes and duration of 1-2 hours, whereas bupivacaine has a significantly longer duration of action of 2-4 hours, but slower onset of > 5 minutes [20] . The optional addition of epinephrine constricts the local vasculature, thereby keeping the anesthetic contained for a longer period and decreasing the systemic absorption, as well as extending the duration of action. Our center generally uses lidocaine to take advantage of quick onset; however, in our experience, bupivacaine decreases post-operative opioid requirements and this is supported in the literature [21] . While some centers have tried mixing solutions of lidocaine with bupivacaine to take advantage both properties, the clinical benefit seems to be narrow [22] .

Adverse effects of lidocaine toxicity include circumoral numbness, tinnitus, altered mental status, seizure, and cardiac arrhythmias; while adverse effects of epinephrine include tachycardia and other sympathetic phenomena [23] .

Clinics should have a protocol in place for the rare case of emergency. This should include emergency transport services to the hospital, a crash cart available, and at least one person performing or supervising the procedure to be ACLS certified and familiar with the treatment of Local Anesthetic Systemic Toxicity (LAST).

Given the high-volume of gynecologic brachytherapy cases at our institution and anticipated lack of operating room resources among the COVID-19 pandemic, we were fortunate to be able to develop and implement a method of analgesia, which allows our patients access to curative brachytherapy without the need for general anesthesia, gynecologists, or support staff other than a single nurse. In our clinic, utilization of multimodality oral medications and PCB has now become standard for patients who are good candidates.

At selection, 5% of patients were excluded from in-clinic PCB insertion for excessive vaginal canal fibrosis. Thus far, 38 insertions have been done on 18 different patients, and only 1 case was aborted (97% success rate). The aborted case was complicated by a delay to beginning the insertion, which resulted in patient's PO analgesia waning. She had history of narcotic abuse and likely was a fast metabolizer of narcotics. According to nursing assessments there was "no pain reported" at the conclusion of the procedure in 95% of cases. We did not formally assess a pain scale during the procedure. Generally, the impact on residency training was positive; the majority of these cases were completed entirely by a resident under direct faculty supervision. Further this has decreased the burden on our trainees whom, under the old protocol, spent valuable time attending to patients in the post-anesthesia care unit prior to transport. Additionally, with brachytherapy cases taking less time, busy trainees may allot their time to other tasks. Residents have become increasingly comfortable with the use of PCBs, and we will continue to use the technique beyond the pandemic in the appropriately selected patient. Not only does it decrease risk to the patient (compared to general or spinal anesthesia), reduce recovery time, and decrease health care cost; but it allows for the entire BT case to be completed in a shorter calendar period, as the brachytherapist is not limited by availability of other services, operating room slots, or hospital transport.

This report describes intracavitary device placement without any interstitial needles. Future directions involve determining the feasibility of PCB and multimodal PO anesthesia for cases in which a hybrid intercavitary/interstitial device is used. Further, we are interested to eventually implement pudendal block which may be ideal for interstitial J o u r n a l P r e -p r o o f perform 3D-based planning, we see no reason why PCB with multimodal oral anesthesia could not also be adapted for conventional point A/B prescription for use in low-resource regions, making curative brachytherapy more accessible globally.

In a multi-disciplinary effort, we have successfully transitioned many ICBT cases to the clinic with the use of PCB local anesthesia and oral multimodality therapy in direct response to the current pandemic, thereby mitigating exposure risk to patients and staff as well as reducing overall health care burden.

The author(s) received no specific funding for this work. The authors report no proprietary or commercial interest in any product or concept discussed in this article. Contouring and treatment planning then occurs. The treatment fraction is administered, device pulled, and patient discharged with responsible adult as early as 10 am. Five mL of 1% lidocaine without epinephrine is injected at the cervicovaginal junction (fornix) represented at 4 o'clock and 8 o'clock with an X over a 30 second period at ~2cm depth. Spinal needle is aspirated prior to injection to ensure no blood return.

Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer

Differences in outcome for cervical cancer patients treated with or without brachytherapy

Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review

A comparative analysis of two different dose fractionation regimens of high dose rate intracavitary brachytherapy in treatment of carcinoma of uterine cervix: A prospective randomized study

Proposed brachytherapy recommendations (practical implementation, indications, and dose fractionation) during COVID-19 pandemic

A study of complications arising from different methods of anesthesia used in high-dose-rate brachytherapy for cervical cancer

Contemporary Approaches to Postoperative Pain Management. Plastic and reconstructive surgery

Postoperative pain management after ambulatory surgery: role of multimodal analgesia

Preemptive, preventive, multimodal analgesia: what do they really mean

Paracervical anesthesia for hysteroscopy and endometrial biopsy in postmenopausal women. A randomized, double-blind, placebo-controlled study. The Journal of reproductive medicine

Refining paracervical block techniques for pain control in first trimester surgical abortion: a randomized controlled noninferiority trial

Paracervical local anaesthesia for cervical dilatation and uterine intervention. Cochrane Database Syst Rev

Paracervical Block for Laminaria Insertion Before Second-Trimester Abortion: A Randomized Controlled Trial

Novel anesthetic technique for combined intracavitary and interstitial brachytherapy for cervix cancer in an outpatient setting

Outpatient combined intracavitary and interstitial cervical brachytherapy: barriers and solutions to implementation of a successful programme-a single institutional experience

MRI-assisted cervix cancer brachytherapy pre-planning, based on application in paracervical anaesthesia

ASA provides examples to each ASA physical status class

Comparison of paracervical block techniques during first trimester pregnancy termination

Neural blockade in clinical anesthesia and management of pain

The effects of incisional bupivacaine on postoperative narcotic requirements, oxygen saturation and length of stay in the post-anesthesia care unit. Acta anaesthesiologica scandinavica

Onset and duration of intradermal mixtures of bupivacaine and lidocaine with epinephrine

StatPearls

Pudendal nerve block in HDRbrachytherapy patients: do we really need general or regional anesthesia?

J o u r n a l P r e -p r o o f